Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pediatrix Medical Group, Inc.MD · Entity 4451 | Pres., PDX & OBX Medical Group | March 01, 2022 | March 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pediatrix Medical Group, Inc.
Report date March 01, 2022 · Filed March 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 109,457 |
Reported balance
After 2022-03-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-03-01 · Tax withholding · Disposed 10,244 · Balance 109,457 F1: Represents 10,244 restricted shares withheld for payment of taxes upon vesting of shares. F2: Includes 12,246 restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan in connection with achievement in excess of target of specified performance-based criteria for the performance period from January 1, 2021 through December 31, 2021. Also includes 64 shares acquired by reporting person through Issuer's Employee Stock Purchase Plan since the last Form 4 filing. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 10,244 restricted shares withheld for payment of taxes upon vesting of shares.
F2: Includes 12,246 restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan in connection with achievement in excess of target of specified performance-based criteria for the performance period from January 1, 2021 through December 31, 2021. Also includes 64 shares acquired by reporting person through Issuer's Employee Stock Purchase Plan since the last Form 4 filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2022 Filed Mar 3, 2022 22:01 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | Tax withholdingCommon Stock | 10,244 | $23.47 | $240,426.68 |
DisclosureSEC source: 0001209191-22-015591 · doc4.xml · nonDerivative · entry 1 Hinson Roger Mack · CIK 0001826596 · Pres., PDX & OBX Medical Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,457 F1 · kind: Represents 10,244 restricted shares withheld for payment of taxes upon vesting of shares. F2 · balance_after: Includes 12,246 restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan in connection with achievement in excess of target of specified performance-based criteria for the performance period from January 1, 2021 through December 31, 2021. Also includes 64 shares acquired by reporting person through Issuer's Employee Stock Purchase Plan since the last Form 4 filing. Read SEC document |
| November 10, 2021 Filed Nov 10, 2021 21:07 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | SaleCommon Stock | 8,800 | $28.38 | $249,744.00 |
DisclosureSEC source: 0001209191-21-063836 · doc4.xml · nonDerivative · entry 1 Hinson Roger Mack · CIK 0001826596 · Pres., PDX & OBX Medical Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,391 F1 · kind: Sales made pursuant to reporting person's 10b5-1 trading plan adopted June 15, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $28.13 to $28.55 for a weighted average sales price of $28.38. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 62 shares acquired by reporting person through Issuer's Employee Stock Purchase Plan since the last Form 4 filing. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 21:01 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | SaleCommon Stock | 8,799 | $32.35 | $284,647.65 |
DisclosureSEC source: 0001209191-21-050907 · doc4.xml · nonDerivative · entry 1 Hinson Roger Mack · CIK 0001826596 · Pres., PDX & OBX Medical Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,129 F1 · kind: Sales made pursuant to reporting person's 10b5-1 trading plan adopted June 15, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in thirty-six (36) separate transactions with prices ranging from $32.01 to $32.67 for an average weighted sale price of $32.35. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 128 shares acquired by the Reporting person through the Issuer's Employee Stock Purchase Plan since the last Form 4 filing. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:38 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | Tax withholdingCommon Stock | 6,244 | $24.43 | $152,540.92 |
DisclosureSEC source: 0001209191-21-016887 · doc4.xml · nonDerivative · entry 3 Hinson Roger Mack · CIK 0001826596 · Pres., PDX & OBX Medical Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,800 F3 · kind: Represents 6,244 shares withheld for payment of taxes upon vesting of shares previously reported. F4 · balance_after: Includes 182 shares acquired by Reporting person through Issuer's Employee Stock Purchase Plan since the last Form 4 filing. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:38 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantCommon Stock | 30,613 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-016887 · doc4.xml · nonDerivative · entry 2 Hinson Roger Mack · CIK 0001826596 · Pres., PDX & OBX Medical Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,862 F2 · kind: Restricted shares granted pursuant to the Issuer's Plan, in connection with an annual equity award. Twenty-five percent (25%) of the restricted shares will vest on March 1, 2022, twenty-five percent (25%) of the restricted shares will vest on March 1, 2023 and fifty percent (50%) of the restricted shares will vest on March 1, 2024. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:38 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | GrantCommon Stock | 30,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-016887 · doc4.xml · nonDerivative · entry 1 Hinson Roger Mack · CIK 0001826596 · Pres., PDX & OBX Medical Group 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,249 F1 · kind: Restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan (the "Plan"), in connection with an annual equity award. The number of shares being reported represents the "target" number of restricted shares and does not include the right of the reporting person to receive up to 15,306 additional shares based on the achievement of certain performance-based criteria for the twelve months ending December 31, 2021. The actual number of shares earned could be less than or greater than the target number, depending on the level of performance achieved, and all of the restricted shares granted are subject to forfeiture if minimum levels of performance are not met. Any restricted shares earned will not vest any earlier than in three installments of twenty-five (25%) on March 1, 2022, twenty-five (25%) on March 1, 2023 and fifty (50%) on March 1, 2024, subject to the terms of the Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.